GSK licenses cancer immunotherapy from Surface Oncology

By The Science Advisory Board staff writers

December 17, 2020 -- GlaxoSmithKline (GSK) has obtained an exclusive license worldwide and commercial rights to Surface Oncology's preclinical program, SRF813, an antitumor antibody.

SRF813 is a fully human immunoglobulin G (IgG1) antibody targeting poliovirus receptor-related immunoglobulin domain-containing (PVRIG), an inhibitory protein expressed on natural killer (NK) cells and T cells. SRF813 binds to a distinct epitope on PVRIG and blocks the interaction of the protein with CD112, which is overexpressed in tumor cells.

In preclinical studies, the candidate promotes activation of both NK cells and T cells and has the potential to elicit strong antitumor responses and immunological memory. SRF813 is currently being evaluated in studies to support an investigational new drug (IND) application with an IND submission planned for 2021.

Under the agreement, GSK will make an $85 million upfront payment to Surface Oncology. In addition, Surface Oncology may receive up to an additional $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.